The estimated Net Worth of Andreas Wicki is at least $297 Milione dollars as of 12 December 2022. Andreas Wicki owns over 28,841 units of Pacira BioSciences Inc stock worth over $27,923,259 and over the last 14 years he sold PCRX stock worth over $268,786,428. In addition, he makes $0 as Independent Director at Pacira BioSciences Inc.
Andreas has made over 53 trades of the Pacira BioSciences Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 28,841 units of PCRX stock worth $1,739,401 on 12 December 2022.
The largest trade he's ever made was selling 909,100 units of Pacira BioSciences Inc stock on 11 March 2013 worth over $25,463,891. On average, Andreas trades about 114,432 units every 73 days since 2011. As of 12 December 2022 he still owns at least 2,147,943 units of Pacira BioSciences Inc stock.
You can see the complete history of Andreas Wicki stock trades at the bottom of the page.
Dr. Andreas Wicki Ph.D. serves as Independent Director of the Company. Dr. Wicki is a life sciences entrepreneur and investor with over 20 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been Chief Executive Officer of HBM Healthcare Investments (Cayman) Ltd. (formerly HBM BioVentures AG) since 2001. From 1998 to 2001, Dr. Wicki was the Senior Vice President of European Analytical Operations at MDS Inc. From 1990 to 1998, he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. From 2007 to 2011, he served as a member of the board of directors of PharmaSwiss SA. Previously, Dr. Wicki held board positions on several privately-held companies and companies listed on international exchanges. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the board of directors of Viela Bio, Inc. (Nasdaq: VIE), Buchler GmbH, Harmony Biosciences, Inc., HBM Healthcare Investments (Cayman) Ltd., HBM BioCapital Ltd. and Vitaeris, Inc.
Andreas Wicki is 61, he's been the Independent Director of Pacira BioSciences Inc since 2006. There are 5 older and 19 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Andreas's mailing address filed with the SEC is GOVERNORS SQUARE,, 23 LIME TREE BAY AVE., PO BOX 30852, GRAND CAYMAN, E9, 00000.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon e Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: